UY33523A - ?vectores de parapoxvirus?. - Google Patents

?vectores de parapoxvirus?.

Info

Publication number
UY33523A
UY33523A UY0001033523A UY33523A UY33523A UY 33523 A UY33523 A UY 33523A UY 0001033523 A UY0001033523 A UY 0001033523A UY 33523 A UY33523 A UY 33523A UY 33523 A UY33523 A UY 33523A
Authority
UY
Uruguay
Prior art keywords
parapoxvirus
vectors
parapoxvirus vectors
recombinant parapoxviruses
parapoxviruses
Prior art date
Application number
UY0001033523A
Other languages
English (en)
Inventor
Olivier Michel Martinon
Nanda Kumar Damavarapu Reddy
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY33523A publication Critical patent/UY33523A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a parapoxvirus recombinantes que comprenden ADN heterólogo derivado de un virus del moquillo canino, a la preparación de dichas construcciones y a su uso en composiciones y vacunas inmunogénicas. Adicionalmente, se refiere al uso de parapoxvirus recombinantes para diagnosis.
UY0001033523A 2010-07-20 2011-07-20 ?vectores de parapoxvirus?. UY33523A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36587010P 2010-07-20 2010-07-20

Publications (1)

Publication Number Publication Date
UY33523A true UY33523A (es) 2012-02-29

Family

ID=44504027

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033523A UY33523A (es) 2010-07-20 2011-07-20 ?vectores de parapoxvirus?.

Country Status (15)

Country Link
US (1) US20120020995A1 (es)
EP (1) EP2595652A1 (es)
JP (1) JP2013537409A (es)
KR (1) KR20130020963A (es)
CN (1) CN103079593A (es)
AR (1) AR082281A1 (es)
AU (1) AU2011281229A1 (es)
BR (1) BR112013001379A2 (es)
CA (1) CA2804890A1 (es)
CL (1) CL2012003737A1 (es)
CO (1) CO6700818A2 (es)
MX (1) MX2013000787A (es)
RU (1) RU2013102413A (es)
UY (1) UY33523A (es)
WO (1) WO2012011045A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015111756A1 (de) 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
CN105749272B (zh) * 2016-03-08 2020-05-12 广州动物园 表达大熊猫犬瘟热病毒h、f基因重组山羊痘病毒的疫苗、其制备方法及免疫应用方法
JP6944324B2 (ja) 2017-09-26 2021-10-06 川崎重工業株式会社 鉄道車両構体
CN108220251B (zh) * 2018-02-11 2022-03-04 南方医科大学 一种重组传染性脓疱溶瘤病毒及其制备方法与应用
JP2021516957A (ja) * 2018-03-07 2021-07-15 トランジェーヌＴｒａｎｓｇｅｎｅ パラポックスウイルスベクター
CN111004783A (zh) * 2019-12-18 2020-04-14 内蒙古元山生物科技有限公司 一种表达猪圆环病毒2型cap蛋白的重组羊口疮病毒，其制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
DE59712852D1 (de) * 1996-02-28 2007-07-19 Bayer Healthcare Ag Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
IL161590A0 (en) 2001-12-10 2004-09-27 Bavarian Nordic As Poxvirus containing formulations and process for preparing stable poxvirus containing compositions
EP2647645B1 (en) 2002-12-17 2016-07-27 AiCuris GmbH & Co. KG Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom

Also Published As

Publication number Publication date
CA2804890A1 (en) 2012-01-26
AR082281A1 (es) 2012-11-28
AU2011281229A1 (en) 2013-01-24
BR112013001379A2 (pt) 2016-05-17
KR20130020963A (ko) 2013-03-04
JP2013537409A (ja) 2013-10-03
EP2595652A1 (en) 2013-05-29
MX2013000787A (es) 2013-08-08
US20120020995A1 (en) 2012-01-26
CL2012003737A1 (es) 2013-10-11
WO2012011045A1 (en) 2012-01-26
CN103079593A (zh) 2013-05-01
RU2013102413A (ru) 2014-08-27
CO6700818A2 (es) 2013-06-28

Similar Documents

Publication Publication Date Title
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
BR112018011881A2 (pt) proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
UY33523A (es) ?vectores de parapoxvirus?.
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
CO6670515A2 (es) Vectores de parapoxvirus
MX2011011505A (es) Vacuna neumococica y usos de la misma.
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
NZ608143A (en) Recombinant modified vaccinia virus ankara (mva) influenza vaccine
BR112015000585A2 (pt) cepas mutantes de mycoplasma hyopneumoniae
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
ECSP12012131A (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quiméricos
MX2019007924A (es) Vacunas contra la influenza.
WO2014008475A3 (en) Compositions and methods related to viral vaccines
CL2013001219A1 (es) Metodo para producir virus monoglucosilado de influenza; virus monoglucosilado del antígeno de influenza ha (virus completo o recombinante); uso del virus para preparar vacuna.
MX350718B (es) Vacuna de rinitis equina.
EP2501405A4 (en) COMPOSITION, METHOD, AND USES OF POX VIRUS ELEMENTS IN VACCINATE CONSTRUCTS
WO2014015287A3 (en) Influenza vaccine consisting of a mva which expresses influenza antigens fused to vaccinia secretory signal sequences
TR201907091T4 (tr) Yeni adjuvan kompozisyonları.
TN2010000479A1 (en) Inactivated live - attenuated bluetongue virus vaccine